Rethinking the role of chemotherapy in haematology and oncology – reflections from EHA 2026
As chemotherapy use declines and targeted therapies assume a larger role in cancer treatment, researchers are looking beyond response rates to focus on real-world feasibility and reducing treatment burden for patients.
One of the defining themes at this year’s European Hematology Association (EHA) Congress was that response rates alone are no longer enough. The field is moving beyond traditional clinical endpoints alone to prioritise improving the full patient experience. Researchers are now looking at how long responses last, how specific treatments affect daily life and how well they work outside the clinical trial setting.
As we develop new therapies, this evolution is shaping how we approach research and clinical development. Increasingly, the focus is not only on individual medicines, but also on therapeutic approaches and modalities that can…
Already a member? Sign-in
